Novartis "can never be done" when it comes to major acquisitions in its sector as it always needs to look for the next "great asset," CEO Vas Narasimhan told CNBC. In order to offset the hit from generics competition Novartis has been on a buying spree, acquiring more than 35 companies over the last year. The Swiss drugmaker announced its biggest deal in a decade on Sunday, when it announced it has agreed to buy U.S. biotechnology company Avidity Biosciences for about $12 billion. The purchase